Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04357821 · ClinicalTrials.gov registry record · Phase 1
Combinatorial Therapy to Induce an HIV Remission
A Phase 1 study of HIV/AIDS, sponsored by University of California, San Francisco.
- Active
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT04357821: Active Phase 1 study of HIV/AIDS, sponsored by University of California, San Francisco.
NCT04357821 is a Phase 1 study of HIV/AIDS that is active but no longer recruiting, run by University of California, San Francisco. The registered enrollment target is 11 participants, below the 33,180-participant average among 61 other HIV/AIDS trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04357821, a Phase 1 study of HIV/AIDS, is active but no longer recruiting, sponsored by University of California, San Francisco.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
Combination approaches will almost certainly be required to generate durable control of HIV in the absence of antiretroviral therapy (a "remission"). In this study, 20 individuals will receive a combination regimen administered during ART and then undergo an analytic treatment interruption (ATI).
Primary Outcome
Number of participants who experience a new grade 3 or greater adverse event
Conditions Studied
Interventions
- DRUG Combination Intervention
Study Locations (1)
California
- Zuckerberg San Francisco General Hospital, University of California San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2020-08-01 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
What the registry record for NCT04357821 still lists
NCT04357821 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 33,180-participant average among 61 other HIV/AIDS trials with a reported enrollment target (100% lower).
The record links to 1 condition, with HIV/AIDS appearing as the primary indexed condition, and to 1 intervention - of which Combination Intervention is the first listed.
NCT04357821 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04357821 about?
NCT04357821 is a clinical study titled "Combinatorial Therapy to Induce an HIV Remission". Combination approaches will almost certainly be required to generate durable control of HIV in the absence of antiretroviral therapy (a "remission"). In this study, 20 individuals will receive a combination regimen administered during ART and then undergo an analytic treatment interruption (ATI).
What is the current status of trial NCT04357821?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2020-08-01. Estimated completion is 2026-06.
What conditions does trial NCT04357821 study?
This clinical trial studies the following conditions: HIV/AIDS.
What interventions are being tested in trial NCT04357821?
The interventions under investigation include: Combination Intervention (DRUG).
Who is sponsoring clinical trial NCT04357821?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04357821 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV/AIDS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04357821's enrollment target sits among peer trials
11 62nd of 61 the lowest of 61 other HIV/AIDS trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV/AIDS trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue
COMPLETED · Phase 1
-
Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens
COMPLETED · Phase 1
-
Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - PK Study
COMPLETED · Phase 1
-
Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)
COMPLETED · Phase 1
-
A Mobile Gaming App to Improve Adherence to PrEP
RECRUITING · NA
-
LinkPositively+ A Mobile Health App Delivered Intervention to Improve HIV Care Outcomes Among Black Women Affected by Mental Health and Violence
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI